Neurocrine’s opicapone shows positive action in late-stage Parkinson’s studies

Neurocrine’s opicapone shows positive action in late-stage Parkinson’s studies
Results from two Phase 3 clinical trials evaluating Neurocrine Biosciences' (NBIX +0.4%) opicapone in Parkinson's disease (PD) patients showed a treatment effect. The data were presented at the ... read more
Source: Bing NewsPublished on 2019-05-06